Moolec Science SA Ordinary Shares and Protalix BioTherapeutics, Inc. Common Stock
Moolec Science SA, a science-based ingredient company, engages in developing ingredients for food, pet food, animal feed, and dietary supplements using molecular farming technology in Cayman Islands and internationally. It produces animal proteins in plants to heal the meat production system. The company is based in Grand Cayman, Cayman Islands.
Open MLEC dashboard ↗Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. It operates in the United States, Australia, Canada, Israel, Brazil, Russia, and Turkey. The company is headquartered in Hackensack. New Jersey.
Open PLX dashboard ↗You've viewed 3 distinct stock or comparison pages today. Sign in for 10 views per day.
Sign in →